Frederic Vallee
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Structure and mechanism of inhibition of lysine demethylase 2A (KDM2A) by compound 183c.
Journal: Communications chemistry
Published: December 17, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.
Journal: Research square
Published: August 06, 2025
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.
Journal: Nature communications
Published: July 06, 2025
Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor.
Journal: Journal of medicinal chemistry
Published: May 16, 2025
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.
Journal: Journal of medicinal chemistry
Published: September 20, 2022
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Journal: Journal of medicinal chemistry
Published: July 26, 2022
Discovery of a Novel Muscarinic Receptor PET Radioligand with Rapid Kinetics in the Monkey Brain.
Journal: ACS chemical neuroscience
Published: October 27, 2017
Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl)phenyl)benzamides as TRPA1 antagonists.
Journal: Bioorganic & medicinal chemistry letters
Published: February 23, 2014
Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists.
Journal: Bioorganic & medicinal chemistry letters
Published: February 23, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026